3-v Biosciences, Inc.

Nektar Therapeutics

Sagimet Biosciences Inc.

Haiying Cai

Cristiana A Zaharia

Russell J Johnson

Lily W Hu

Robert S McDowell

Johan D Oslob

Marc Evanchik

Hanbiao Yang

Neel Kumar Anand

Bo-Liang Deng

Zhongxu Ren

Allan S Wagman

Bhalchandra V Joshi

Saul Kivimae

Timothy Sean Heuer

Yamini Ohol-Gupta

Marie O'Farrell

Gregory Duke

Takahiro Miyazaki

Jonathan Zalevsky

Robert S Mcdowell

Marie O'farrell

Lin Cheng

Wen Zhang

Natalia Aurrecoechea

Donogh John Roger O'Mahony

Mary Tagliaferri

Werner Rubas

Rhoneil L Pena

Marlene Hennessy

Anthony James Brockway

Greg Duke

Timothy Heuer

Yamini Ohol

Marie O'FARRELL

The instant disclosure provides novel adenosine receptor antagonist compounds, compositions, methods of making and methods of using. In a further aspect, a method of treating a subject in need thereof, comprising administering a therapeutically effective amount of any one or more of the compounds described herein. In some embodiments, the subject has cancer and the method is a method of treating cancer.

Adenosine 2 receptor antagonists

Provided are multi-arm polymer conjugates of Toll-Like Receptor (“TLR”) agonists such as TLR 7/8 agonists, as well as related compositions, and methods of making and using such conjugates. Exemplary conjugates are encompassed by Formula I: or a pharmaceutically acceptable salt form thereof, where R, taken together with each Q, is a residue of a polyol, polythiol, or polyamine bearing from 3 to about 50 hydroxyl, thiol, or amino groups; each Q is a linker selected from oxygen, sulfur and —NH; each POLY is independently a water-soluble, non-peptidic polymer; each Xis independently a linkage-containing spacer moiety; q is a positive integer from 3 to about 50; and each TLR 7/8 AG is a Toll-like receptor 7/8 agonist. Also provided is a method of administering to a patient having cancer (a) an IL-2Rβ-activating amount of a long-acting, IL-2Rβ-selective agonist; and (b) a Toll-like receptor agonist such as a conjugate as described above, as well as related compositions, kits and methods.

Multi-arm polymer conjugates of TLR agonist compounds and related immunotherapeutic treatment methods

Provided is a method of administering to a patient having cancer: (a) a 4-1BB agonist; (b) an IL-2Rβ-activating amount of a long-acting, IL-2Rβ-selective agonist; and/or (c) a toll-like receptor agonist, as well as related compositions, kits and compositions.

Immunotherapeutic tumor treatment method

Disclosed herein are methods in the field of cancer immunotherapy that involve the treatment of a subject having cancer by administering to the subject a toll-like receptor 7/8 (TLR7/8) agonist in combination with a long-acting IL-2Rβ-biased agonist and a programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) axis inhibitor, and related compositions, dosage forms, and kits.

Provided are multi-arm polymer conjugates of Toll-Like Receptor ('TLR') agonists such as TLR 7/8 agonists, as well as related compositions, and methods of making and using such conjugates. Exemplary conjugates are encompassed by Formula I: (I) or a pharmaceutically acceptable salt form thereof, where R, taken together with each Q, is a residue of a polyol, polythiol, or polyamine bearing from 3 to about 50 hydroxyl, thiol, or amino groups; each Q is a linker selected from oxygen, sulfur and &#x2014;NH; each POLY is independently a water-soluble, non-peptidic polymer; each Xr is independently a linkage-containing spacer moiety; q is a positive integer from 3 to about 50; and each TLR 7/8 AG is a Toll-like receptor 7/8 agonist. Also provided is a method of administering to a patient having cancer (a) an IL-2R&#x3b2;-activating amount of a long-acting, IL-2R&#x3b2;-selective agonist; and (b) a Toll-like receptor agonist such as a conjugate as described above, as well as related compositions, kits and methods.RQ-POLY-Xr-TLR7/8 AG)&#x2003;&#x2003;(I)

Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by dysregulation of a fatty acid synthase pathway by the administration of such compounds and combinations of such compounds and other therapeutic agents.

Heterocyclic modulators of lipid synthesis and combinations thereof

Compounds that are fatty acid synthesis modulators are provided. The compounds may be used to treat disorders characterized by disregulation of the fatty acid synthase function by modulating the function and/or the fatty acid synthase pathway. Methods are provided for treating such disorders including viral infections, such as hepatitis C infection, cancer and metabolic disorders.

Heterocyclic modulators of lipid synthesis

Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by disregulation of a fatty acid synthase pathway by the administration of such compounds.

Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by dysregulation of a fatty acid synthase pathway by the administration of such compounds.

Heterocyclic modulators of lipid synthesis for use against cancer and viral infections

Growing community of inventors

Cupertino, CA, United States of America

Haiying Cai